用于推导心血管风险预测方程的当代队列中的治疗退出。

IF 5.1 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Heart Pub Date : 2024-08-14 DOI:10.1136/heartjnl-2024-324179
Jingyuan Liang, Rodney T Jackson, Romana Pylypchuk, Yeunhyang Choi, Claris Chung, Sue Crengle, Pei Gao, Corina Grey, Matire Harwood, Anders Holt, Andrew Kerr, Suneela Mehta, Susan Wells, Katrina Poppe
{"title":"用于推导心血管风险预测方程的当代队列中的治疗退出。","authors":"Jingyuan Liang, Rodney T Jackson, Romana Pylypchuk, Yeunhyang Choi, Claris Chung, Sue Crengle, Pei Gao, Corina Grey, Matire Harwood, Anders Holt, Andrew Kerr, Suneela Mehta, Susan Wells, Katrina Poppe","doi":"10.1136/heartjnl-2024-324179","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>No routinely recommended cardiovascular disease (CVD) risk prediction equations have adjusted for CVD preventive medications initiated during follow-up (treatment drop-in) in their derivation cohorts. This will lead to underestimation of risk when equations are applied in clinical practice if treatment drop-in is common. We aimed to quantify the treatment drop-in in a large contemporary national cohort to determine whether equations are likely to require adjustment.</p><p><strong>Methods: </strong>Eight de-identified individual-level national health administrative datasets in Aotearoa New Zealand were linked to establish a cohort of almost all New Zealanders without CVD and aged 30-74 years in 2006. Individuals dispensing blood-pressure-lowering and/or lipid-lowering medications between 1 July 2006 and 31 December 2006 (baseline dispensing), and in each 6-month period during 12 years' follow-up to 31 December 2018 (follow-up dispensing), were identified. Person-years of treatment drop-in were determined.</p><p><strong>Results: </strong>A total of 1 399 348 (80%) out of the 1 746 695 individuals in the cohort were not dispensed CVD medications at baseline. Blood-pressure-lowering and/or lipid-lowering treatment drop-in accounted for 14% of follow-up time in the group untreated at baseline and increased significantly with increasing predicted baseline 5-year CVD risk (12%, 31%, 34% and 37% in <5%, 5-9%, 10-14% and ≥15% risk groups, respectively) and with increasing age (8% in 30-44 year-olds to 30% in 60-74 year-olds).</p><p><strong>Conclusions: </strong>CVD preventive treatment drop-in accounted for approximately one-third of follow-up time among participants typically eligible for preventive treatment (≥5% 5-year predicted risk). Equations derived from cohorts with long-term follow-up that do not adjust for treatment drop-in effect will underestimate CVD risk in higher risk individuals and lead to undertreatment. Future CVD risk prediction studies need to address this potential flaw.</p>","PeriodicalId":12835,"journal":{"name":"Heart","volume":null,"pages":null},"PeriodicalIF":5.1000,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Treatment drop-in in a contemporary cohort used to derive cardiovascular risk prediction equations.\",\"authors\":\"Jingyuan Liang, Rodney T Jackson, Romana Pylypchuk, Yeunhyang Choi, Claris Chung, Sue Crengle, Pei Gao, Corina Grey, Matire Harwood, Anders Holt, Andrew Kerr, Suneela Mehta, Susan Wells, Katrina Poppe\",\"doi\":\"10.1136/heartjnl-2024-324179\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>No routinely recommended cardiovascular disease (CVD) risk prediction equations have adjusted for CVD preventive medications initiated during follow-up (treatment drop-in) in their derivation cohorts. This will lead to underestimation of risk when equations are applied in clinical practice if treatment drop-in is common. We aimed to quantify the treatment drop-in in a large contemporary national cohort to determine whether equations are likely to require adjustment.</p><p><strong>Methods: </strong>Eight de-identified individual-level national health administrative datasets in Aotearoa New Zealand were linked to establish a cohort of almost all New Zealanders without CVD and aged 30-74 years in 2006. Individuals dispensing blood-pressure-lowering and/or lipid-lowering medications between 1 July 2006 and 31 December 2006 (baseline dispensing), and in each 6-month period during 12 years' follow-up to 31 December 2018 (follow-up dispensing), were identified. Person-years of treatment drop-in were determined.</p><p><strong>Results: </strong>A total of 1 399 348 (80%) out of the 1 746 695 individuals in the cohort were not dispensed CVD medications at baseline. Blood-pressure-lowering and/or lipid-lowering treatment drop-in accounted for 14% of follow-up time in the group untreated at baseline and increased significantly with increasing predicted baseline 5-year CVD risk (12%, 31%, 34% and 37% in <5%, 5-9%, 10-14% and ≥15% risk groups, respectively) and with increasing age (8% in 30-44 year-olds to 30% in 60-74 year-olds).</p><p><strong>Conclusions: </strong>CVD preventive treatment drop-in accounted for approximately one-third of follow-up time among participants typically eligible for preventive treatment (≥5% 5-year predicted risk). Equations derived from cohorts with long-term follow-up that do not adjust for treatment drop-in effect will underestimate CVD risk in higher risk individuals and lead to undertreatment. Future CVD risk prediction studies need to address this potential flaw.</p>\",\"PeriodicalId\":12835,\"journal\":{\"name\":\"Heart\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":5.1000,\"publicationDate\":\"2024-08-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Heart\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1136/heartjnl-2024-324179\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Heart","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/heartjnl-2024-324179","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

背景:常规推荐的心血管疾病(CVD)风险预测方程均未对其推导队列中随访期间开始使用的心血管疾病预防药物(放弃治疗)进行调整。如果辍药现象很普遍,那么在临床实践中应用该方程时就会低估风险。我们的目的是量化当代大型全国队列中的治疗退出情况,以确定是否可能需要对方程进行调整:方法:我们将新西兰奥特亚罗瓦地区八个去标识化的个人层面国家卫生行政数据集连接起来,建立了一个队列,其中包括 2006 年几乎所有无心血管疾病、年龄在 30-74 岁之间的新西兰人。研究人员对 2006 年 7 月 1 日至 2006 年 12 月 31 日(基线配药)期间配发降压和/或降脂药物的个人,以及截至 2018 年 12 月 31 日的 12 年随访期间(随访配药)每 6 个月配发降压和/或降脂药物的个人进行了识别。结果:在队列中的 1 746 695 人中,共有 1 399 348 人(80%)在基线时未配发心血管疾病药物。在基线时未接受降压和/或降脂治疗的人群中,放弃降压和/或降脂治疗的时间占随访时间的14%,并且随着预测的基线5年心血管疾病风险的增加而显著增加(结论中的12%、31%、34%和37%):在通常符合预防性治疗条件(5 年预测风险≥5%)的参与者中,放弃心血管疾病预防治疗约占随访时间的三分之一。从长期随访的队列中得出的等式如果不调整治疗退出效应,就会低估高风险人群的心血管疾病风险,导致治疗不足。未来的心血管疾病风险预测研究需要解决这一潜在缺陷。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Treatment drop-in in a contemporary cohort used to derive cardiovascular risk prediction equations.

Background: No routinely recommended cardiovascular disease (CVD) risk prediction equations have adjusted for CVD preventive medications initiated during follow-up (treatment drop-in) in their derivation cohorts. This will lead to underestimation of risk when equations are applied in clinical practice if treatment drop-in is common. We aimed to quantify the treatment drop-in in a large contemporary national cohort to determine whether equations are likely to require adjustment.

Methods: Eight de-identified individual-level national health administrative datasets in Aotearoa New Zealand were linked to establish a cohort of almost all New Zealanders without CVD and aged 30-74 years in 2006. Individuals dispensing blood-pressure-lowering and/or lipid-lowering medications between 1 July 2006 and 31 December 2006 (baseline dispensing), and in each 6-month period during 12 years' follow-up to 31 December 2018 (follow-up dispensing), were identified. Person-years of treatment drop-in were determined.

Results: A total of 1 399 348 (80%) out of the 1 746 695 individuals in the cohort were not dispensed CVD medications at baseline. Blood-pressure-lowering and/or lipid-lowering treatment drop-in accounted for 14% of follow-up time in the group untreated at baseline and increased significantly with increasing predicted baseline 5-year CVD risk (12%, 31%, 34% and 37% in <5%, 5-9%, 10-14% and ≥15% risk groups, respectively) and with increasing age (8% in 30-44 year-olds to 30% in 60-74 year-olds).

Conclusions: CVD preventive treatment drop-in accounted for approximately one-third of follow-up time among participants typically eligible for preventive treatment (≥5% 5-year predicted risk). Equations derived from cohorts with long-term follow-up that do not adjust for treatment drop-in effect will underestimate CVD risk in higher risk individuals and lead to undertreatment. Future CVD risk prediction studies need to address this potential flaw.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Heart
Heart 医学-心血管系统
CiteScore
10.30
自引率
5.30%
发文量
320
审稿时长
3-6 weeks
期刊介绍: Heart is an international peer reviewed journal that keeps cardiologists up to date with important research advances in cardiovascular disease. New scientific developments are highlighted in editorials and put in context with concise review articles. There is one free Editor’s Choice article in each issue, with open access options available to authors for all articles. Education in Heart articles provide a comprehensive, continuously updated, cardiology curriculum.
期刊最新文献
Clinical and echocardiographic parameters associated with outcomes in patients with moderate secondary mitral regurgitation. Managing cardiogenic shock and left ventricular outflow tract obstruction in Takotsubo syndrome: current insights and challenges. New-onset atrial fibrillation after coronary surgery and stroke risk: a nationwide cohort study. Genetic variants associated with cardiac hypertrophy-related sudden cardiac death and cardiovascular outcomes in a Finnish population. Too fast, too furious
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1